Los ensayos aleatorios que examinaron la eficacia de los agonistas de GLP-1 para perder peso no fueron diseados para capturar estos eventos debido al pequeo tamao de las muestras y al corto seguimiento
These medications are prepared by pharmacists to meet specific patient needs and are often shipped from FDA-registered, inspected compounding pharmacies
A systematic review and meta-analysis indicated that liraglutide 3.0 mg led to an average weight loss of 5.24 kg, whereas semaglutide 2.4 mg resulted in a loss of 12.47 kg
What separates the compounded and branded paths in the article's comparison table
In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )
the two require separate evidence
